Emami Limited (531162) Earnings Call Transcript
November 5, 2026
Earnings Call Speaker Segments
Ladies and gentlemen, good day, and welcome to Emami Limited Q2 FY '27 Earnings Conference Call hosted by IIFL Capital Services Limited. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Siddhesh Deshmukh from IIFL Capital Services Limited. Thank you, and over to you, sir.
Good afternoon, everyone. I have the pleasure to host the management of Emami Limited for the 2Q FY '27 Earnings Call. From the management, we have with us Mr. Mohan Goenka, Whole Time Director and Vice Chairman; Mr. Vivek Dhir, CEO, International Business; Mr. Dhruv Aggarwal, Chief Growth Officer; Mr. Gul Raj Bhatia, President, Healthcare; Mr. Manish Gupta, President, Sales; and Mr. Rajesh Sharma, President, Finance and IR. And I'll hand over the call to Mr. Mohan Goenka for his opening remarks, post which we'll open the floor for Q&A. Over to you, sir.
Good afternoon, ladies and gentlemen. Thank you for joining us today for Emami Limited's Q2 ' 27 Earnings Call. Building on the strong momentum from Q1, we have had another quarter of broad-based strong double-digit growth with both our core brands and our strategic investments performing well. Let me walk you through the highlights for the quarter. Our consolidated revenue grew by 36% to INR 1,088 crores. Domestic sales grew by 49%, driven by volume growth of 43%. On a like-to-like basis, considering previous period's revenue of Axiom and IncNut Digital, consolidated sales grew by 24% and Domestic Business grew 32% with a volume growth of 26%. Category-wise, Skin Care grew by 31%. This was led by robust growth in our Talc portfolio, which grew by over 2x in the quarter. BoroPlus grew in near 20s and Smart & Handsome delivered double-digit growth. Hair & Scalp Care grew by 30% during the quarter. Navratna Oil grew in the 30s and Kesh King grew in high teens. We also launched Kesh King Scalp First range in modern trade and e-com. And I must call out 7 Oils in One, which continued its remarkable run and nearly doubled its sales this quarter. It is now one of the fastest-growing brands in our core portfolio. Healthcare range grew by 11% with Pain Management range growing in the teens. OTC portfolio also performed well and grew in high teens. Medico range posted a steady single-digit growth. Now coming to strategic investments portfolio. On a like-to-like basis, we grew by an impressive 73% and contributed approximately 26% of our domestic business. Axiom and Brillare more than doubled their sales. IncNut grew by over 50% and The Man Company by over 30%. We expanded Axiom in modern trade chains and quick com, and we invested in building visibility for the AloFrut brand. For IncNut, we are now expanding beyond D2C into marketplaces. We have commenced operations on quick com, and we have also entered into new international markets. When I step back and look at all of this together, both our core portfolio and our strategic investments are going strongly, and they are doing so side by side. We are deliberately building a more diversified business, one that spans traditional FMCG, personal and health care; and two, the premium beauty and grooming, digital-first brands and emerging consumer platforms. This diversification does 2 things. It widens our growth runway, and it makes the business more resilient across different economic and consumption cycles. Our channel transformation is moving steady at a steady pace. Organized channels now contribute to 37% of our domestic business. Modern trade and e-com both maintained strong momentum and quick com now accounts for around 15% of our digital sales. This is a significant shift in how our consumers are choosing to shop with us. On our international business, Q2 performance was impacted by a few specific external disruptions with revenue declining by 2%. Importantly, the weakness was not broad-based. Nepal was impacted by severe floods. And Gulf markets continue to face supply chain challenges arising from ongoing regional conflicts. Excluding Nepal and Iraq, our international business grew by 6%. Inflationary pressures remained elevated through the quarter and the sharp rise in input costs widened our margins -- weighted on our margins. Together with the changing business mix following the integration of the acquired business, this resulted in higher COGS and a moderation in gross margin by 520 basis points compared to last year. Despite these pressures, EBITDA grew by 25% to INR 222 crores and profit before tax grew by 29% to INR 194 crores. I think this reflects the resilience of our business model and the effectiveness of the cost management initiatives our teams undertook during the quarter. Profit after tax stood at INR 144 crores, lower by 3%, and that is largely due to the normalization of our effective tax rate following the phase out of fiscal benefits. Looking at the first half of FY '27, revenue stood at INR 2,127 crores, up 25%. EBITDA was at INR 449 crores, up 15% and profit before tax, INR 388 crores, growing by 15%. On capital allocation, we completed our share buyback worth INR 281 crores last month to buy back 73 lakh shares. The Board has also approved the first interim dividend of INR 5 per share, which would amount to a payout of INR 214 crores. As we look ahead, we remain very optimistic about the growth prospects of the business. We are encouraged by the strong performance of our core brands, the rapid scaling of our digital-first brands and sustained traction in modern trade, e-com and quick com. Commodity inflation and geopolitical developments remain areas to watch for. However, our diversified portfolio, strengthened distribution, robust innovation pipeline and disciplined cost management position us well to deliver sustained profitable growth through the remainder of FY '27. With that, I would now like to open the floor for questions. Thank you.
[Operator Instructions] The first is from the line of Abneesh Roy from Nuvama.
Congrats on great numbers. My first question is on the new launches, a lot of new launches. I want to focus on only 2 for now. On the Maa range and on the Kesh King Scalp First range, both of these -- you seem to be a slightly late entrant. So if you could tell us versus the existing strong players in both segments, how is your pricing? And you have tried premium personal care earlier also. So from that, what are the learnings? What are you doing different this time? And how was the success of the premium personal care, which you have tried earlier? If you can discuss that also. That is my first question.
So Abneesh, as far as the baby care range is concerned, of course, we are trying it on -- firstly on e-com and modern trade. What is differential is our prices are firstly not as expensive as the other products in the market. It is almost 25% to 50% cheaper depending on the product range, okay? So we are looking really at a mass market compared to some of the others. The market size is almost INR 30,000 crores to INR 40,000 crores, okay? And BoroPlus being purely Ayurveda, we have launched under the brand BoroPlus. So we will try it out. Of course, we are highlighting some ingredients like special almonds, kashmiri kesar, whatever is the ingredients. So let us see. I think we are well positioned as far as price and e-com, quick com is concerned. Then of course, it would depend on the market. But we are going to, this time, focus a little more as far as the baby care range is concerned. And the Kesh King Scalp First is, again, another -- we wanted to expand Kesh King brand. This time, it is a premium product, pricing almost in the range of INR 500 to INR 1,000. Let us see. Again, we have now strong presence in e-com and quick com with our other products. So our relationships there, we understand how that market works. And so this is a new entry as far as Kesh King is concerned. We want to take Kesh King brand slightly towards the premium side of it, yes.
One follow-up question on the Kesh King First Scalp. Of course, at that price point, hard science will work. So are you focusing more on taking this as a brand extension? Or there is a real consumer need, which is getting filled, which will require hardcore R&D. So I wanted to ask on, is there something on the product side, which is really differentiating apart from, say, the very good packaging, very good brand extension, et cetera. Anything disruptive on the product formulation?
Absolutely. And in fact, we are heavily relying on the R&D side of it because if you see into the details of it, it has some ingredients which are unique. We are calling it detoxifying scalp and [indiscernible] or something. So these are like -- we are relying heavily on the R&D. The consumers have become very intelligent. They now read the levels. And we are also going to highlight on these platforms, the ingredient side of it. That's why they're coming at a big premium.
Understood. Last question, on your strategic investment, congrats, very good numbers there...
But they are, of course, much cheaper than the L'Oreal or the other Derma Co, Pilgrim. They are still at a lower end of it.
Understood. Last question on strategic investment, Mohanji. So here, there is a 5% acceleration quarter-on-quarter. So if you can discuss on the profitability side, clearly, these are currently in the gestation phase. I wanted to understand, is there any improvement on the profit metrics versus Q1? And on the four brands, you did give out the revenue growth numbers specifically. But where is the confidence level higher from a medium, long term on those four subsegments within the strategy? Where is the highest confidence you are getting this year, of course, being first year of relaunch or some of them are new, growth rates are very, very robust. I don't think that may give us the full picture. I wanted to understand from your own initial targets versus what you are getting, where is the confidence level higher?
Yes. So Dhruv is there. I would pass it on to Dhruv to answer. But these are not new brands, Abneesh. These have been in the market for quite some time. We have been [indiscernible] it over.
Yes, a lot of relaunch has happened, Man Company and all that.
Yes, yes. So Dhruv will answer.
I think we are up 5% versus the H1 number, but overall versus Q1, we are actually up 12%. So that if I remember correctly, Q1 was at 51% growth. Now the reason -- I think if you ask me which are the ones that I have a lot of confidence on, I have a plan for -- or we have a plan for all 4 of them, right? So whether it is Brillare, TMC, Axiom or IncNut. I think all 4 of them, there are different levers, very, very different levers that we are going across. TMC was one, I think that was a little stagnant, we got it moving to high 20% margins and now this quarter, it's up 30% plus. So we're very confident that those plans are working. It has to do with reformulation, making sure that we have the best product offering to customers and then marketing that is the way that consumers are looking at [indiscernible] for some of the other brands, I think that's just a very different set of initiatives across all, and I don't see any reason why we can't continue this growth. To achieve this kind of growth, I think everything has to fire. Even if one of the brands goes down, you won't see these sort of numbers. So [indiscernible], will we continue to see a 70%? Probably not, but definitely, strong growth there across all four.
Abneesh, there's a lot happening. Of course, as Dhruv said, 70% is aggressive numbers, but we are also hiring a lot of new talent, a lot of R&D is going into -- many of the products are going to come into -- some of the products are going to come into GT. So there are huge plans going forward for all the four product ranges.
The next question is from the line of Harit Kapoor from Investec.
Just one question was on the profitability side of things. So obviously, to support the growth and in terms of the new brands typically are at higher A&P spend, we've seen the A&P ratios being a tad higher, not too much higher actually. I just wanted to understand that do we see this broad ratio, which is around 20% last year? Should we assume that this structurally is a bit higher for the next 2 years as we look to not only add get the B2C brands up and running at a good pace, but also at an organic level, you seem to be significantly adding to the portfolio. So just wanted to get a color on kind of A&P to sales thought, where should this land over the next 2 years as you are in a significant investment phase.
So Harit, we are definitely on spending mode because our focus has been growing the top line. After many, many quarters, we are seeing our domestic business, particularly our core portfolio firing and many, many brands. So at this point of time, we are not really thinking of 0.5%, 1% here and there. Wherever we are finding opportunities, we are wanting to spend on advertising. But having said that, I think you should take in the range of 18% to 19% max on A&P spends for the whole year -- for the full year.
And the second bit was on -- sorry, the second bit was on the core portfolio. I mean everything is core now as far as India is concerned. But I just wanted to understand 2 things. One is what is the extent of price increases that you had to take to offset this level of inflation? And does some of it come in, in the quarters going forward? And the second piece was on rural. If you could just give us a sense of -- I know your channel mix is changing and rural salience probably going down. But I just wanted your sense on how rural is outlook is, how you are seeing things on the ground even in Q2 and in October. This is in the context of inflation, rainfall deficit, et cetera, et cetera. Are you seeing pockets where there is a little bit volatility? So those are my 2 questions.
So Harit, as far as price increase is concerned, it has been in the range of 5.5% for the full year. Whatever cost increases have happened, absolutely, we have passed on to the consumers, okay? But -- and as far as rural is concerned, some markets, particularly in South and West, where we have seen significantly less rainfall and drought-like situations, there the rural markets have not performed so well, particularly for some of our brands. But by and large, some pockets of UP have also not done so well. But many districts have performed very, very well, where we have seen good rainfalls. o it has been a mixed bag, but now we are entering into the peak season as far as winter is concerned. Post Diwali, I think things should pick up now.
The next question is from the line of Arnab Mitra from Goldman Sachs.
Mohanji, congratulations on a very strong quarter. My first question was on the core business. If I look at the first half, I know this quarter had a slightly low base because of the GST-related issues last year. If you look at the first half growth of the core business, how do you think of the second half growth? Because there has been a lot of shifts of timing of festivity. There is also the GST upstock, destock. So generally, as we look at for second half versus first half, what's your sense of how the core business could be doing?
So Arnab, we are seeing the momentum continuing. And we expect our this business to grow anywhere between 18% to 20% for the second half.
Got it. So this is the total and...
Yes, total. Everything put together. Yes.
Understood. And Mohanji, about the international business, the decline has become lesser this quarter. But again, there, given the supply chain changes and all, if you could give us an update on how is the situation right now and therefore, what you expect?
Yes. So Vivek, our international CEO, is there. Vivek, could you throw some light?
[Audio Gap] Based. It has been only in, say, a couple of geographies where we couldn't manage the growth over there. But most of the other places, we have grown. So when you look at coming months, last 2, 3 months, growth are being observed in many, many places. We have like turned around business in Bangladesh, GCC because of the OTC hazardous goods, which is contributing around 2% of our business, that is still on a hold. We are not able to move the goods from India to other places. So that is still remaining unresolved issue for us. But otherwise, we are moving ahead on growth in almost every geography now. So I think worst is behind us in international.
And Arnab, October -- Vivek, if you can correct me, I think October month was positive for the international business.
Yes, sir. It was high double digits, yes.
Yes. So I think we are on the growth path, Arnab, now.
Got it. And my last question is on margins. So if I look at the gross margin impact this quarter, which is around 500 basis point increase in our raw material cost. So how much of this, Mohanji, is kind of fundamental because your mix has changed towards the newer categories? And how much of this is driven by input cost inflation where, let's say, between pricing and if crude comes off, do you think you will be able to recover back?
Arnab, almost out of 550 basis points, 400 basis points was purely RM cost and balance was the mix. But I'm very confident, Arnab, that once we see these -- the second half is going to be higher because we have procured it at these prices now. But now I think going forward, we should benefit out of these input corrections, which will be for next year.
The next question is from the line of Rahul from Bowhead.
Congratulations on a great set of numbers, Mohanji. So I had a question like at the end of quarter 1, you had given a guidance for strategic investment to hit around INR 750 crores to INR 800 crores. And we have hit around INR 240 crores kind of run rate in this quarter. So do you think there is a scope to upgrade guidance on that?
Yes. Dhruv, would you want to throw some light?
We'll do INR 800 crores plus this year for sure.
Yes, should keep it at INR 850 crores. [Foreign Language] if you take as the run rate, then it would be almost INR 1,000 crores to INR 1,100 crores.
Right. sir, international, sir, actually Dabur reported yesterday, and they reported double digit in Middle East and 33% in Bangladesh. So is our supply chain very different from what Dabur does in those countries?
So Dabur has almost like 11 manufacturing locations outside of India, different locations. The geography of play is, I think, quite different. Our overlap happens only in probably GCC and Bangladesh for that matter. So inflation has been felt almost everywhere and price increases, consequent scheme reductions we have been able to do. But most of our geographies, when you look at my presence is there in Russia, Ukraine, that's again a disturbed geography but it's growing for us. Similarly GCC, and at the same markets to be Hormuz like Iraq, which suffered quite a bit in quarter 2 for me, almost 0 sale. We were not able to move goods to Iraq at all, now found alternate routes and moving to Port Aqaba. And those type of limitations are not there with those companies. They are doing business in U.S., they are doing in Africa, South Africa, Nigeria and with manufacturing locations over there. So we have limited manufacturing in India, Bangladesh, UAE and then Germany around. And plus we are having a toll manufacturing in Thailand as well, but the goods need to move into the markets where we have the business. So even the Black Sea route till Russia and other things were disturbed during the quarter, which other companies do not face those type of issues. So issue listing of Dabur or probably Godrej or Marico will be different than what we are facing.
[Operator Instructions] The next question is from the line of from Saksham Tyagi from Desvelado Advisory.
So my question is, sir, in the previous con call, you mentioned that you are creating a data analytics and AI platform. So I just wanted an update, like, I just wanted to know what's the progress so far? And what will be impact once the work is completed?
Yes. So Manish is leading this AI...
Saksham, could you repeat your query, please? I couldn't really hear it properly.
Sure, sir. In the previous con call, you mentioned that you are creating a data analytics and AI platform. So I just wanted to know like what's the progress so far and what will be the impact once the work is done, related to the AI, data and all?
All right. Okay. So we are progressing on track. In fact, we are a little ahead and that gladens us. What we are doing is essentially digitizing and using AI for our end-to-end processes right from forecasting till the fulfillment. So our entire process, whether it's supply chain in between invoicing and the distributor-led frontline booking all these processes are being revamped through new technology, new tools as well as putting AI work. I mean I think the progress we are making is superb and more results will come in the following quarters as we complete the transitions.
Is there any given time line for that or something?
So we are expecting that we should be able to complete this in the next quarter. So April onwards, we should start seeing real gains. We are already seeing in pilot phases in some markets we have done, we are getting some very impressive results.
Okay, sir. Understood, sir. And my second question is on the growth side. Since the international business declined nearly 7% on a year-on-year basis. So how are you planning to turn the growth rate positive? And by when can we actually expect some positive change in that?
International business is already in green now. So when we look at October and September as well as August, we are moving into the green. Initial months, when things were being realigned, we had lost some business. So one part of my business, which is not there with any of the company is the OTC goods, which is Pain Management, which moves. A part of that is categorized as hazardous due to the spay and gaseous form goods. So those movement is still curtailed, and we are not able to move goods out of India at the moment. So that contributes roughly around 2% of my global business, the part which I'm not able to move out. So that also continues to put pressure, but we are into the green territory for the last 3 months now.
Okay. So we are in profit on quarter-on-quarter basis, right?
On behalf of IIFL Capital Services Limited and Emami Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.
Thank you. Thank you, everyone, for joining us today for our Q2 quarterly results. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Emami Limited transcript - plus 260,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Emami Limited earnings transcripts and 260,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $145 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.